Digestive Health Newsletter

Raising a Child with Inflammatory Bowel Disease

Marla C. Dubinsky, MD

Volume 10, 
February 01, 2008

by Marla C. Dubinsky, MD

Marla Dubinsky Dr. Dubinsky's main research interests are health outcomes and the epidemiology and genetic influences of IBD in children. Her objective is to study the influence of genetics and immune responses on the variability in clinical presentations of early onset IBD. Additional interests include the study of pharmacogenetics to evaluate how heredity influences drug responses and attempt to optimize and individualize the management of IBD. Dr. Dubinsky has written for numerous peer reviewed journals including Gastroenterology, Journal of Pediatric Gastroenterology, Inflammatory Bowel Diseases and the American Journal of Gastroenterology. In addition, she has authored book chapters for Trends in Inflammatory Bowel Disease and Inflammatory Bowel Disease: Diagnosis and Therapeutics. Dr. Dubinsky has lectured widely at both a national and international level. Dr. Dubinsky received her bachelor's degree from the University of Western Ontario and her medical degree from Queen's University in Canada. She completed her clinical pediatric gastroenterology training in Montreal, Canada.

Table of Contents

Introduction

If you have recently learned that your child has inflammatory bowel disease (IBD), you are probably feeling concerned and perhaps overwhelmed. But keep in mind that your child is not alone – about 1.4 million people in the U.S. have IBD, and about 140,000 of them are under age 18. Although IBD is a chronic disease, that doesn't mean that your child has to feel sick every day. There are many things you can do to help your child keep symptoms under control. In fact, most people with IBD are healthy more often than they are sick. This newsletter will help you understand your child's diagnosis and treatment, as well as the steps you can take to help your child manage the disease.

Back to Top

How Does the Digestive System Work?

To understand IBD, it is often helpful to first understand how the digestive system works. When you eat, food moves from your mouth into your esophagus, where it passes down into your stomach. There, it is mixed and diluted before it passes on to your small intestine (also called the small bowel), where it is broken down and absorbed. Sections of the small intestine include the duodenum, jejunum, and ileum. From the small intestine, anything unabsorbed moves into your large intestine (also called the colon), where water is absorbed. The remaining "stool" passes into your rectum and is eliminated through your anus.

Colon

Back to Top

What is IBD?

IBD is a general term used to describe a group of illnesses that cause inflammation of the digestive system. There is no such thing as a "typical patient" – symptoms tend to vary from person to person. The most common symptoms are diarrhea (sometimes bloody and often with extreme urgency), stomach cramping or pain, weight loss, dehydration, fatigue, loss of appetite, and nausea. Other extra–intestinal symptoms may include arthritis, eye inflammation, skin rashes, and/or fever. IBD can be especially difficult to diagnose in children, as some children have very subtle gastrointestinal symptoms but present with growth failure as the only sign of inflammation. IBD also tends to be unpredictable, with intermittent flare–ups followed by periods of remission. It is not contagious and can be controlled with treatment, but there is no cure.

The two most common types of IBD are Crohn's disease (CD) and ulcerative colitis (UC). CD can occur anywhere along the digestive system, from the mouth to the anus. It causes patches of inflammation, swelling, and ulcers, interspersed with healthy tissue. CD can penetrate through all of the layers of the digestive tract tissue, making it difficult for the body to absorb nutrients from food. In contrast, UC occurs only in the large intestine and always involves the rectum. It causes inflammation, swelling, and ulcers, but affects only the inner lining (mucosa) of the digestive tract. UC makes it difficult for the body to reabsorb water into the bloodstream. For more details about CD and UC, refer to the "Clinical Course of IBD" newsletter.

Back to Top

How is IBD Diagnosed?

There is no single test that can be used to definitively diagnose CD or UC, and a child with IBD may appear quite healthy. A physician will typically take a medical history and conduct a thorough physical examination. Typical tests may include:

Back to Top

How is IBD Treated?

Medication

The primary purpose of treatment with medication is to control inflammation and reduce pain and other symptoms. The medications used for children are the same as those used for adults, however dosages must be adjusted to each child's weight. It is also important to consider potential side effects and compliance issues. Most IBD medications are taken orally; others are taken intravenously, as an enema, or as a suppository. The five major types of IBD medication are:

Note that children taking immunosuppressive medications should not receive live vaccinations (e.g., chicken pox, MMR, rotavirus, or oral polio).

For more information about IBD medication, refer to the "Treatment of IBD," "Staying on Medication," and "Medication Side Effects" newsletters.

Nutrition

What your child eats cannot cause IBD, but it can affect symptoms during flare–ups. It often takes trial and error to figure out which foods are problematic. You may find that keeping a food diary can help track patterns. It also may be helpful to meet with a dietitian to discuss questions and concerns. Keep in mind that many children do not need to make significant changes to their diet.

Some children with IBD are also lactose intolerant. This means that they do not have enough lactase, which is the enzyme that digests lactose (a sugar found in milk and milk products). Typical symptoms are cramps and diarrhea following meals. Treatment commonly involves avoiding certain dairy foods (again, often a matter of trial and error) or taking lactose–free milk products, soy milk, or lactase enzyme tablets before eating dairy foods.

Because IBD interrupts the digestive system and can interfere with the body's ability to absorb nutrients, your child may not grow as quickly as his peers. Children with IBD typically catch up eventually, but puberty may be delayed. Your child may need supplemental nutrition to maintain normal growth and development, especially if he is too sick to eat properly, if his digestive tract needs a rest, or if diarrhea is causing excessive nutrient loss. There are three general categories of supplemental nutrition:

For more information, refer to the "IBD and Nutrition" newsletter.

Surgery

If medication does not control your child's IBD symptoms, surgery may become necessary. The goals of surgery differ, depending on whether your child has CD or UC. For CD, surgery can help relieve the disease symptoms. For example, it can be used to repair infected areas or fistulas (opening from the intestine to other organs), to remove an obstruction and widen the intestine (strictureplasty), and/or to remove a diseased portion of the intestine and join the two healthy ends together (resection).

For UC, surgery can cure the disease by removing all of the diseased tissue. This typically takes place in multiple stages, with weeks between stages to allow healing. First, most of the large intestine and the lining of the rectum are removed. (Over time, the small intestine will adapt to take over the large intestine functions). Then, an opening (called an "ostomy") is created in the abdomen, to which the end of the remaining small intestine is attached. Liquid waste moves through the small intestine into a small bag (often called an "appliance") attached to the skin with special adhesive. Ostomy appliances can be worn discretely under clothing. Finally, during a later surgery, the lowest part of the remaining small intestine can often be reattached to the anal opening (ileoanal pouch anastomosis), and the ostomy in the abdominal wall is closed.

Back to Top

How Can I Help My Child Cope?

At School

If you have a school–aged child with IBD, it will bolster his confidence to know that a support system is in place at school. Be sure to notify his teacher and the school nurse. The nurse can help you inform and educate other school personnel. Remember to formulate a plan for medication administration, urgent bathroom needs, and school absences. You may want to arrange to keep an extra pair of underwear in the nurse's office. Don't forget to discuss any special needs regarding physical education and/or field trips with the appropriate teacher.

When Traveling

There is no reason that your child's IBD should limit your family's travel plans, as long as he is feeling well. All it takes is a little advance planning. For example, make it a habit to always know where the closest bathroom is before the need is urgent. And carry an extra pair of underwear, just in case. For more specific tips about traveling by car, traveling by plane, and avoiding travelers' diarrhea, refer to the "IBD and Your Lifestyle" newsletter.

In the Hospital

Hospitals can be frightening places for children, but there are many things you can do to help your child feel more relaxed and comfortable. For a younger child, try role–playing with a toy doctor's kit and read age–appropriate books about going to the hospital. For an older child, encourage questions and participation in decision–making. No matter what the age of your child, be sure to pack comforting items from home, like favorite pajamas and stuffed animals. Stay with your child as much as possible, encourage siblings to visit, and try to maintain family routines. Be sure to acknowledge your child's fears and feelings, and answer questions in a truthful, developmentally appropriate manner.

In General

Children react to chronic illness in many different ways. Watch for signs of depression and anxiety, which may occur soon after diagnosis or some time later. Remember that such reactions are a response to IBD and not its cause. You may find it helpful to meet with a mental health professional who has experience working with children and chronic disease.

As a parent, you have the opportunity to significantly influence your child's ability to cope with IBD. It is in your child's best interest to gradually foster independence in an age–appropriate way. For example, children with IBD can learn to become responsible for taking their medication, keeping a food diary, and communicating with their physician. If you are positive and supportive, your child will learn to take his illness in stride and focus on life beyond IBD.

Back to Top

Summary

You will play a key role in helping your child learn to take charge of his disease. Flare–ups and surgery may be inevitable, but a positive attitude and a handful of coping skills can go a long way toward facilitating an active, productive life. Improved treatment options are available each year, and the past decade has seen significant advances toward finding a cure for IBD. Until then, you can keep your child as healthy as possible by making sure he takes his medication regularly, pays attention to his diet, has a support system in place at school, and is well prepared if surgery becomes necessary.

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter